Data gathered: November 27
Alternative Data for Sagimet Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Google Trends | 59 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,193 | Sign up | Sign up | Sign up |
| Twitter Followers | 177 | Sign up | Sign up | Sign up |
| Twitter Mentions | 45 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 24 | Sign up | Sign up | Sign up |
About Sagimet Biosciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways.
| Price | $5.54 |
| Target Price | Sign up |
| Volume | 483,960 |
| Market Cap | $191M |
| Year Range | $2.47 - $6.19 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Comparing Sagimet Biosciences (NASDAQ:SGMT) & Evotec (NASDAQ:EVO)November 27 - ETF Daily News |
 |
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 25 - Yahoo |
 |
HC Wainwright Reaffirms “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT)November 18 - ETF Daily News |
|
Sagimet Biosciences Inc. Reports Financial Results for Q3 2024 and Regulatory ProgressNovember 18 - ETF Daily News |
|
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024November 17 - Yahoo |
 |
Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.November 17 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 4.2M | -4.2M | -15M | -17M | -0.455 |
| Q2 '24 | 0 | 4.3M | -4.3M | -8.1M | -11M | -0.250 |
| Q1 '24 | 0 | 3.5M | -3.5M | -6.6M | -8.8M | -0.230 |
| Q4 '23 | 0 | 3.8M | -3.8M | -8.2M | -6.8M | -0.780 |
| Q3 '23 | 2M | 4.5M | -2.5M | -6.4M | -7.5M | -0.350 |
Insider Transactions View All
| Kemble George filed to sell 118,693 shares at $3.2. July 25 '24 |
| Martins Eduardo Bruno filed to sell 81,213 shares at $3.1. July 23 '24 |
| Kemble George filed to sell 142,318 shares at $3.1. July 23 '24 |
| Rozek Elizabeth filed to sell 160,506 shares at $3.1. July 23 '24 |
| Happel David filed to buy 639,200 shares at $5.3. March 28 '24 |
Similar companies
Read more about Sagimet Biosciences (SGMT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Sagimet Biosciences?
The Market Cap of Sagimet Biosciences is $191M.
What is the current stock price of Sagimet Biosciences?
Currently, the price of one share of Sagimet Biosciences stock is $5.54.
How can I analyze the SGMT stock price chart for investment decisions?
The SGMT stock price chart above provides a comprehensive visual representation of Sagimet Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sagimet Biosciences shares. Our platform offers an up-to-date SGMT stock price chart, along with technical data analysis and alternative data insights.
Does SGMT offer dividends to its shareholders?
As of our latest update, Sagimet Biosciences (SGMT) does not offer dividends to its shareholders. Investors interested in Sagimet Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Sagimet Biosciences?
Some of the similar stocks of Sagimet Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.